Janssen HLA - Search Results

1

Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes.

Lau DTY, Ganova-Raeva L, Wang J, Mogul D, Chung RT, Lisker-Melman M, Chang KM, Shaikh OS, Janssen HLA, Wahed AS, Lok AS; Hepatitis B Research Network. Lau DTY, et al. Among authors: janssen hla. Hepatology. 2021 May;73(5):1637-1651. doi: 10.1002/hep.31506. Hepatology. 2021. PMID: 32860463 Free PMC article.

2

Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial.

Janssen HL, Berk L, Heijtink RA, ten Kate FJ, Schalm SW. Janssen HL, et al. Hepatology. 1993 Mar;17(3):383-8. Hepatology. 1993. PMID: 8444411 Clinical Trial.

3

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. van Zonneveld M, et al. Hepatology. 2004 Mar;39(3):804-10. doi: 10.1002/hep.20128. Hepatology. 2004. PMID: 14999700

4

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Stoop JN, et al. Hepatology. 2005 Apr;41(4):771-8. doi: 10.1002/hep.20649. Hepatology. 2005. PMID: 15791617

5

The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.

Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. Leemans WF, et al. J Hepatol. 2006 Mar;44(3):507-11. doi: 10.1016/j.jhep.2005.12.004. Epub 2006 Jan 19. J Hepatol. 2006. PMID: 16457904

6

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.

ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. ter Borg MJ, et al. Hepatology. 2006 Sep;44(3):721-7. doi: 10.1002/hep.21302. Hepatology. 2006. PMID: 16941701 Clinical Trial.

7

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group. Buster EH, et al. Hepatology. 2007 Aug;46(2):388-94. doi: 10.1002/hep.21723. Hepatology. 2007. PMID: 17604363 Clinical Trial.

8

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL. Rijckborst V, et al. Hepatology. 2010 Aug;52(2):454-61. doi: 10.1002/hep.23722. Hepatology. 2010. PMID: 20683945 Clinical Trial.

9

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Roomer R, et al. Hepatology. 2010 Oct;52(4):1225-31. doi: 10.1002/hep.23842. Hepatology. 2010. PMID: 20830784

10

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Sonneveld MJ, et al. Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844. Hepatology. 2010. PMID: 20830787 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

574 results

Search Page

Filters